Review



reference american type culture collection 19977  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC reference american type culture collection 19977
    Reference American Type Culture Collection 19977, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1171 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/reference+american+type+culture+collection+19977/pmc12772275-130-5-6?v=ATCC
    Average 99 stars, based on 1171 article reviews
    reference american type culture collection 19977 - by Bioz Stars, 2026-06
    99/100 stars

    Images



    Similar Products

    99
    ATCC reference american type culture collection 19977
    Reference American Type Culture Collection 19977, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/reference+american+type+culture+collection+19977/pmc12772275-130-5-6?v=ATCC
    Average 99 stars, based on 1 article reviews
    reference american type culture collection 19977 - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC m abscessus reference strain american type culture collection
    ABL/PI5P reduces <t>Mycobacterium</t> <t>abscessus</t> intracellular viability in macrophages from PWCF irrespective of ETI therapeutic regimen eligibility. Monocyte-derived macrophages from PWCF under an ETI regimen (n = 15) ( A ) or from PWCF without a modulator regimen (n = 15) ( B ) were cultured at a concentration of 1 × 10 6 cells/mL in 96-well plates. Cells were then infected with M. abscessus at multiplicity of infection 10 for 3 hours and finally stimulated with ABL/PI5P and/or ETI for 18 hours. Replication index was calculated as the ratios between the colony-forming units obtained after 18 hours from infection, in the presence or absence of stimuli, and those obtained immediately after infection. For a deeper analysis of the results, patients with CF represented in ( B ) were divided into 2 groups: ( C ) those eligible (n = 8) and ( D ) not eligible (n = 7) for the ETI therapeutic regimen. The results are shown as mean ± standard deviation of the values obtained. Statistical analysis was performed by 2-sided Wilcoxon matched-pairs signed rank test. * P < .05, ** P < .01 *** P < .001, **** P < .0001. If not indicated by the line, the comparisons were performed versus control. Abbreviations: ABL/PI5P, apoptotic body-like liposome/phosphatidylinositol 5-phosphate; PWCF, people with cystic fibrosis; ETI, elexacaftor, tezacaftor, ivacaftor; ns, not significant.
    M Abscessus Reference Strain American Type Culture Collection, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/reference+american+type+culture+collection+19977/pmc12308664-13-0-4?v=ATCC
    Average 99 stars, based on 1 article reviews
    m abscessus reference strain american type culture collection - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    99
    ATCC mab reference strain american type culture collection
    ABL/PI5P reduces <t>Mycobacterium</t> <t>abscessus</t> intracellular viability in macrophages from PWCF irrespective of ETI therapeutic regimen eligibility. Monocyte-derived macrophages from PWCF under an ETI regimen (n = 15) ( A ) or from PWCF without a modulator regimen (n = 15) ( B ) were cultured at a concentration of 1 × 10 6 cells/mL in 96-well plates. Cells were then infected with M. abscessus at multiplicity of infection 10 for 3 hours and finally stimulated with ABL/PI5P and/or ETI for 18 hours. Replication index was calculated as the ratios between the colony-forming units obtained after 18 hours from infection, in the presence or absence of stimuli, and those obtained immediately after infection. For a deeper analysis of the results, patients with CF represented in ( B ) were divided into 2 groups: ( C ) those eligible (n = 8) and ( D ) not eligible (n = 7) for the ETI therapeutic regimen. The results are shown as mean ± standard deviation of the values obtained. Statistical analysis was performed by 2-sided Wilcoxon matched-pairs signed rank test. * P < .05, ** P < .01 *** P < .001, **** P < .0001. If not indicated by the line, the comparisons were performed versus control. Abbreviations: ABL/PI5P, apoptotic body-like liposome/phosphatidylinositol 5-phosphate; PWCF, people with cystic fibrosis; ETI, elexacaftor, tezacaftor, ivacaftor; ns, not significant.
    Mab Reference Strain American Type Culture Collection, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/reference+american+type+culture+collection+19977/pm38364332-43-7-10?v=ATCC
    Average 99 stars, based on 1 article reviews
    mab reference strain american type culture collection - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    Image Search Results


    ABL/PI5P reduces Mycobacterium abscessus intracellular viability in macrophages from PWCF irrespective of ETI therapeutic regimen eligibility. Monocyte-derived macrophages from PWCF under an ETI regimen (n = 15) ( A ) or from PWCF without a modulator regimen (n = 15) ( B ) were cultured at a concentration of 1 × 10 6 cells/mL in 96-well plates. Cells were then infected with M. abscessus at multiplicity of infection 10 for 3 hours and finally stimulated with ABL/PI5P and/or ETI for 18 hours. Replication index was calculated as the ratios between the colony-forming units obtained after 18 hours from infection, in the presence or absence of stimuli, and those obtained immediately after infection. For a deeper analysis of the results, patients with CF represented in ( B ) were divided into 2 groups: ( C ) those eligible (n = 8) and ( D ) not eligible (n = 7) for the ETI therapeutic regimen. The results are shown as mean ± standard deviation of the values obtained. Statistical analysis was performed by 2-sided Wilcoxon matched-pairs signed rank test. * P < .05, ** P < .01 *** P < .001, **** P < .0001. If not indicated by the line, the comparisons were performed versus control. Abbreviations: ABL/PI5P, apoptotic body-like liposome/phosphatidylinositol 5-phosphate; PWCF, people with cystic fibrosis; ETI, elexacaftor, tezacaftor, ivacaftor; ns, not significant.

    Journal: The Journal of Infectious Diseases

    Article Title: Phosphatidylinositol 5-Phosphate-Loaded Apoptotic Body-Like Liposomes for Mycobacterium abscessus Infection Management in Patients With Cystic Fibrosis

    doi: 10.1093/infdis/jiaf124

    Figure Lengend Snippet: ABL/PI5P reduces Mycobacterium abscessus intracellular viability in macrophages from PWCF irrespective of ETI therapeutic regimen eligibility. Monocyte-derived macrophages from PWCF under an ETI regimen (n = 15) ( A ) or from PWCF without a modulator regimen (n = 15) ( B ) were cultured at a concentration of 1 × 10 6 cells/mL in 96-well plates. Cells were then infected with M. abscessus at multiplicity of infection 10 for 3 hours and finally stimulated with ABL/PI5P and/or ETI for 18 hours. Replication index was calculated as the ratios between the colony-forming units obtained after 18 hours from infection, in the presence or absence of stimuli, and those obtained immediately after infection. For a deeper analysis of the results, patients with CF represented in ( B ) were divided into 2 groups: ( C ) those eligible (n = 8) and ( D ) not eligible (n = 7) for the ETI therapeutic regimen. The results are shown as mean ± standard deviation of the values obtained. Statistical analysis was performed by 2-sided Wilcoxon matched-pairs signed rank test. * P < .05, ** P < .01 *** P < .001, **** P < .0001. If not indicated by the line, the comparisons were performed versus control. Abbreviations: ABL/PI5P, apoptotic body-like liposome/phosphatidylinositol 5-phosphate; PWCF, people with cystic fibrosis; ETI, elexacaftor, tezacaftor, ivacaftor; ns, not significant.

    Article Snippet: M. abscessus reference strain American Type Culture Collection (ATCC) 19977 and the M. abscessus subsp abscessus clinical strain Mab285 (previously referred to as CP07), a representative of the dominant clone 1 of M. abscessus subsp abscessus , were used [ ].

    Techniques: Derivative Assay, Cell Culture, Concentration Assay, Infection, Standard Deviation, Control

    ABL/PI5P-amikacin combined treatment reduces Mab285 intracellular viability in macrophages of PWCF who do not receive ETI therapeutic regimen. MDM from PWCF without a modulator regimen (n = 6) were cultured at a concentration of 1 × 10 6 cells/mL in 96-well plates. Cells were then infected with Mycobacterium abscessus at multiplicity of infection 10 for 3 hours and stimulated with ABL/PI5P and/or 4 µg/mL amikacin for 18 hours. Finally, supernatant was collected, and MDM were lysed to enumerate extracellular ( A ) and intracellular ( B ) bacteria. Replication index was calculated as the ratio between the colony-forming units obtained 18 hours after infection in the presence or absence of ABL/PI5P and/or amikacin, and those obtained immediately after infection and before the stimuli. The results are shown as mean ± standard deviation of the values obtained. Statistical analysis was performed by 2-sided Wilcoxon matched-pairs signed rank test. * P < .05. If not indicated by the line, the comparisons were performed versus control. Abbreviations: ABL/PI5P, apoptotic body-like liposome/phosphatidylinositol 5-phosphate; PWCF, people with cystic fibrosis; ETI, elexacaftor, tezacaftor, ivacaftor; MDM, monocyte-derived macrophages; ns, not significant.

    Journal: The Journal of Infectious Diseases

    Article Title: Phosphatidylinositol 5-Phosphate-Loaded Apoptotic Body-Like Liposomes for Mycobacterium abscessus Infection Management in Patients With Cystic Fibrosis

    doi: 10.1093/infdis/jiaf124

    Figure Lengend Snippet: ABL/PI5P-amikacin combined treatment reduces Mab285 intracellular viability in macrophages of PWCF who do not receive ETI therapeutic regimen. MDM from PWCF without a modulator regimen (n = 6) were cultured at a concentration of 1 × 10 6 cells/mL in 96-well plates. Cells were then infected with Mycobacterium abscessus at multiplicity of infection 10 for 3 hours and stimulated with ABL/PI5P and/or 4 µg/mL amikacin for 18 hours. Finally, supernatant was collected, and MDM were lysed to enumerate extracellular ( A ) and intracellular ( B ) bacteria. Replication index was calculated as the ratio between the colony-forming units obtained 18 hours after infection in the presence or absence of ABL/PI5P and/or amikacin, and those obtained immediately after infection and before the stimuli. The results are shown as mean ± standard deviation of the values obtained. Statistical analysis was performed by 2-sided Wilcoxon matched-pairs signed rank test. * P < .05. If not indicated by the line, the comparisons were performed versus control. Abbreviations: ABL/PI5P, apoptotic body-like liposome/phosphatidylinositol 5-phosphate; PWCF, people with cystic fibrosis; ETI, elexacaftor, tezacaftor, ivacaftor; MDM, monocyte-derived macrophages; ns, not significant.

    Article Snippet: M. abscessus reference strain American Type Culture Collection (ATCC) 19977 and the M. abscessus subsp abscessus clinical strain Mab285 (previously referred to as CP07), a representative of the dominant clone 1 of M. abscessus subsp abscessus , were used [ ].

    Techniques: Cell Culture, Concentration Assay, Infection, Bacteria, Standard Deviation, Control, Derivative Assay